The Annual San Antonio Breast Cancer Symposium was held on December 7-10, 2021. Read below for highlights from the meeting, including promising results about a new oral hormone therapy drug, a drug with activity against brain metastases in people with HER2-positive MBC, and genomic testing to guide MBC treatment choices.
Summary of Results From SABCS
Summary by Anne Loeser: Highlights from 2021 SABCS for People Living with MBC
Elacestrant (Oral Hormone Therapy Drug For Hormone Receptor-Positive MBC)
- Breastcancer.org: Experimental Elacestrant Shows Promise for Pre-Treated Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Breastcancer.org (podcast): Experimental Elacestrant: A Standard of Care for Pre-Treated, Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer?
Fam-trastuzumab Deruxtecan-nxki (T-DXd) (For HER2-positive MBC, Including Brain Metastases)
- OncLive: Subgroup Analyses Support T-DXd as Second-Line Standard in HER2+ MBC
- Healio (video): DESTINY-Breast03 Shows Intercranial Responses to Trastuzumab Deruxtecan
Genomic Testing To Guide MBC Treatment Choices
Last Modified on January 12, 2022